Prospects of clinical trials for novel therapeutic approaches in celiac disease

Celiac disease (CD) is a chronic a multifactorial immune-mediated systemic inflammatory disease of the small intestine caused by genetic and environmental factors, elicited by the ingestion of dietary gluten products and related prolamines. This was to provide a broad overview of the completed clinical trials of various novel treatment approaches that are emerging in the current literature, summarising the latest clinical advances of published work from these clinical trials, as well as the possibilities for using them in future clinical practice for CD treatment. A systematic literature search was carried out using PRISMA guidelines and searching through different databases of the clinical trials of novel treatment approaches for CD treatment. Most of the retrieved publications were concerning latiglutenase and larazotide as the two drugs currently undergoing most of the clinical trials to mitigate gluten sensitisation. On the other hand, the results of blocking IL-15 with PRN15 were somewhat disappointing and may have significant adverse effects. Patients who are inevitably suffering from dietary limitations may find hope in these innovative therapies, although it is yet unclear how effective, in the long run, these medications will be useful in treating CD-related extraintestinal symptoms and disorders.